Japan's Astellas to Buy U.S. Drugmaker OSI for $4 Bil.
By wchung | 04 Jul, 2026
Astellas Pharma Inc., Japan’s No. 2 drug maker, said Monday it will buy U.S. cancer drug company OSI Pharmaceuticals Inc. for $4 billion in cash in a bid to expand its cancer drug business worldwide.
Astellas said it will pay $57.50 per OSI share, up from $52 the Japanese company had offered earlier. The transaction will be completed within a month.
The acquisition is part of Astellas’ drive to expand its cancer drug business worldwide. OSI’s drugs include Tarceva, for lung cancer, which generated $1.2 billion in global sales last year.
The Japanese maker said it hopes to jointly develop cancer drugs with OSI.
Apart from cancer, OSI focuses on oncology, diabetes and obesity treatments.
TOKYO (AP)
© 2026 by Asian Media Group Inc.
Recent Articles
- Keiko Fujimori Declared Winner of Peru Presidential Race
- Mass Grief at Khamenei Funeral Suggests Hardline Grip Continues
- AI Turbocharged a Startup, Restructures the Economy
- US-EU Trade Hits Record High Despite Tariff Tensions, Study Shows
- Chinese Independent Refiners Snap up Discounted Mideast Oil as Supplies Rise
- US Oil Companies See Big Profit Jump, Faces Pressure to Cut Pump Prices
- Drug Gangs Use Social Media to Recruit Thai Air Crew as Couriers
- Ghonhee Lee's Katalyst Launches Orbital Rescue Mission for NASA Satellite
- Zuckerberg Says Meta AI Agent Tech Progressing Slower Than Expected
- Japan's Services Activity Returned to Growth in June